A retrospective analysis of etiology and outcomes of hemophagocytic lymphohistiocytosis in children and adults
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare but severe, life-threatening inflammatory condition if untreated. We aimed to investigate the etiologies, outcomes, and risk factors for death in children and adults with HLH. Methods: The medical records of patients who met the HLH criteria of two regional university hospitals in Korea between January 2001 and December 2019 were retrospectively investigated. Results: Sixty patients with HLH (35 children and 25 adults) were included. The median age at diagnosis was 7.0 years (range, 0.1–83 years), and the median follow-up duration was 8.5 months (range, 0–204 months). Four patients had primary HLH, 48 patients had secondary HLH (20 infection-associated, 18 neoplasm-associated, and 10 autoimmune-associated HLH), and eight patients had HLH of unknown cause. Infection was the most common cause in children (14/35, 40.0%), whereas neoplasia was the most common cause in adults (13/25, 52.0%). Twenty-eight patients were treated with HLH-2004/94 immunochemotherapy. The 5-year overall survival (OS) rate for all HLH patients was 59.9%. The 5-year OS rates for patients with primary, infection-associated, neoplasm-associated, autoimmune-associated, and unknown cause HLH were 25.0%, 85.0%, 26.7%, 87.5%, and 62.5%, respectively. Using multivariate analysis, neoplasm-induced HLH (p=0.001) and a platelet count <50×109/L (p=0.008) were identified as independent risk factors for poor prognosis in patients with HLH. Conclusion: Infection was the most common cause of HLH in children, while it was neoplasia in adults. The 5-year OS rate for all HLH patients was 59.9%. HLH caused by an underlying neoplasm or a low platelet count at the time of diagnosis were risk factors for poor prognosis.
Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare but severe, life-threatening inflammatory condition if untreated. We aimed to investigate the etiologies, outcomes, and risk factors for death in children and adults with HLH. Methods: The medical records of patients who met the HLH criteria of two regional university hospitals in Korea between January 2001 and December 2019 were retrospectively investigated. Results: Sixty patients with HLH (35 children and 25 adults) were included. The median age at diagnosis was 7.0 years (range, 0.1–83 years), and the median follow-up duration was 8.5 months (range, 0–204 months). Four patients had primary HLH, 48 patients had secondary HLH (20 infection-associated, 18 neoplasm-associated, and 10 autoimmune-associated HLH), and eight patients had HLH of unknown cause. Infection was the most common cause in children (14/35, 40.0%), whereas neoplasia was the most common cause in adults (13/25, 52.0%). Twenty-eight patients were treated with HLH-2004/94 immunochemotherapy. The 5-year overall survival (OS) rate for all HLH patients was 59.9%. The 5-year OS rates for patients with primary, infection-associated, neoplasm-associated, autoimmune-associated, and unknown cause HLH were 25.0%, 85.0%, 26.7%, 87.5%, and 62.5%, respectively. Using multivariate analysis, neoplasm-induced HLH (p=0.001) and a platelet count <50×109/L (p=0.008) were identified as independent risk factors for poor prognosis in patients with HLH. Conclusion: Infection was the most common cause of HLH in children, while it was neoplasia in adults. The 5-year OS rate for all HLH patients was 59.9%. HLH caused by an underlying neoplasm or a low platelet count at the time of diagnosis were risk factors for poor prognosis.
참고문헌 (24)
- Henter JI, "Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation", Blood, 100, pp.2367~2373 (2002)
- Janka GE, "Familial and acquired hemophagocytic lymphohistiocytosis", Eur J Pediatr, 166, pp.95~109 (2007)
- Janka GE, "Familial hemophagocytic lymphohistiocytosis", Eur J Pediatr, 140, pp.221~230 (1983)
- Henter JI, "Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis", Hematol Oncol Clin North Am, 12, pp.417~433 (1998)
- Jordan MB, "How I treat hemophagocytic lymphohistiocytosis", Blood, 118, pp.4041~4052 (2011)
- Sieni E, "Familial hemophagocytic lymphohistiocytosis : when rare diseases shed light on immune system functioning", Front Immunol, 5, pp.167~ (2014)
- Aricò M, "Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society", Leukemia, 10, pp.197~203 (1996)
- Henter JI, "Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society", Semin Oncol, 18, pp.29~33 (1991)
- Henter JI, "HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society", Med Pediatr Oncol, 28, pp.342~347 (1997)
- Trottestam H, "Chemoimmunotherapy for hemophagocytic lymphohistiocytosis : long-term results of the HLH-94 treatment protocol", Blood, 118, pp.4577~4584 (2011)
- Henter JI, "HLH-2004 : diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis", Pediatr Blood Cancer, 48, pp.124~131 (2007)
- Bergsten E, "Confirmed efficacy of etoposide and dexamethasone in HLH treatment : long-term results of the cooperative HLH-2004 study", Blood, 130, pp.2728~2738 (2017)
- Koh KN, "Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in Korea: report of a nationwide survey from Korea Histiocytosis Working Party", Eur J Haematol, 94, pp.51~59 (2015)
- Trizzino A, "Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations", J Med Genet, 45, pp.15~21 (2008)
- Zur Stadt U, "Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A", Hum Mutat, 27, pp.62~68 (2006)
- Ramos-Casals M, "Adult haemophagocytic syndrome", Lancet, 383, pp.1503~1516 (2014)
- Kleynberg RL, "Secondary hemophagocytic lymphohistiocytosis in adults : an update on diagnosis and therapy", Clin Adv Hematol Oncol, 10, pp.726~732 (2012)
- Lee H, "Natural killer cell function tests by flowcytometry-based cytotoxicity and IFN-γ production for the diagnosis of adult hemophagocytic lymphohistiocytosis", Int J Mol Sci, 20, pp.5413~ (2019)
- Ishii E, "Nationwide survey of hemophagocytic lymphohistiocytosis in Japan", Int J Hematol, 86, pp.58~65 (2007)
- La Rosée P, "Recommendations for the management of hemophagocytic lymphohistiocytosis in adults", Blood, 133, pp.2465~2477 (2019)
- Cetica V, "Genetic predisposition to hemophagocytic lymphohistiocytosis : Report on 500 patients from the Italian registry", J Allergy Clin Immunol, 137, pp.188~196 (2016)
- Chen X, "Genetic variant spectrum in 265 Chinese patients with hemophagocytic lymphohistiocytosis: molecular analyses of PRF1, UNC13D, STX11, STXBP2, SH2D1A, and XIAP", Clin Genet, 94, pp.200~212 (2018)
- Jin Z, "Primary hemophagocytic lymphohistiocytosis in adults : the utility of family surveys in a single-center study from China", Orphanet J Rare Dis, 13, pp.17~ (2018)
- Hayden A, "Hemophagocytic syndromes(HPSs)including hemophagocytic lymphohistiocytosis(HLH)in adults : a systematic scoping review", Blood Rev, 30, pp.411~420 (2016)